ORPHA:100085
Primary hepatic neuroendocrine carcinoma
Publications
758
82.4th percentile
Trials
0
Interventional, condition-specific
Researchers
1,149
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Primary hepatic neuroendocrine carcinoma (PHNEC) is a rare hepatic tumor that may manifest with abdominal pain or fullness, as well as diarrhea or weight loss. More than 10% of cases are asymptomatic and in rare cases a carcinoid syndrome may be observed.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015072
- UMLS:C3273031
- NCIT:C96787
Additional Mondo synonyms (8)
HNEC · PHNEC · hepatic neuroendocrine carcinoma · liver neuroendocrine cancer · liver neuroendocrine carcinoma · neuroendocrine carcinoma of liver · primary hepatic neuroendocrine carcinoma · primary liver neuroendocrine carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
758 matched papers (460 in last 10 years) Source
- Phenotype characterisedPresent
38 HPO annotations (e.g. Neuroendocrine neoplasm; Abdominal distention; Chronic fatigue) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 170 for broader category neuroendocrine carcinoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
38
Associated phenotypes · MONDO:0015072
- Neuroendocrine neoplasm
- Abdominal distention
- Chronic fatigue
- Hepatic cysts
- Right ventricular failure
Showing 5 of 38 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
758
758 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
758 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
460 in the last 10 years · medium confidence · 82.4th percentile (publications denominator)
Phrase hits: 758 · MeSH hits: 0
Who's working on it?
1,149
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang H6 papers · 2026
Department of Surgery, Dongguan Nancheng Hospital, Dongguan, China.
Papers in Europe PMC - 02Liu J5 papers · 2026
Shandong Province Health Precision Medicine Industry Technology Research Institute, Jinan, Shandong, China.
Papers in Europe PMC - 03Wu Y5 papers · 2025
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.
Papers in Europe PMC - 04Zhang W5 papers · 2024
Department of Otolaryngology-Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Otolaryngological Institute, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Sleep Disordered Breathing, Shanghai, China. Electronic address: drzhangwt@163.com.
Papers in Europe PMC - 05Zhang X5 papers · 2026
Department of Radiology, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China.
Papers in Europe PMC - 06Chen Y4 papers · 2024
Department of Hepatobiliary Surgery of General Hospital of PLA, Beijing, 100853, China; Email: chenyongl301@163.com.
Papers in Europe PMC - 07Li J4 papers · 2025
Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 08Li X4 papers · 2026
Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China.
Papers in Europe PMC - 09Zhang L4 papers · 2026
Department of Ultrasound Diagnosis, Gansu Provincial Maternity and Child-care Hospital Lanzhou, Gansu, China.
Papers in Europe PMC - 10Zhang T4 papers · 2025
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. tpingzhang@yahoo.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial. 170 trials are registered for neuroendocrine carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
170 interventional trials matched neuroendocrine carcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: neuroendocrine carcinoma
170
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06941480·NOT YET RECRUITING·A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Conditions: Neuroendocrine Tumor of the Lung · Neuroendocrine Carcinoma of Lung · Neuroendocrine Carcinoma · Neuroendocrine Carcinoma of Prostate·Matched via name phrase
- NCT06479811·RECRUITING·[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Conditions: Sinonasal Neuroendocrine Carcinoma · Nasopharyngeal Carcinoma · Esthesioneuroblastoma · Olfactory Neuroblastoma·Matched via name phrase
- NCT06424665·RECRUITING·A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)·Matched via name phrase
- NCT07458906·RECRUITING·DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Conditions: DLL3-expressing Tumors · PET / CT · Neuroendocrine Cancer·Matched via name phrase
- NCT05312671·RECRUITING·Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Conditions: Small Cell Neuroendocrine Carcinoma of Bladder · Bladder Cancer · Urothelial Carcinoma Bladder·Matched via name phrase
- NCT03866382·RECRUITING·Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Conditions: Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma · Bladder Neuroendocrine Carcinoma·Matched via name phrase
- NCT05969860·RECRUITING·At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Conditions: Advanced Anal Carcinoma · Advanced Biliary Tract Carcinoma · Advanced Bladder Carcinoma · Advanced Breast Carcinoma·Matched via name phrase
- NCT06816394·NOT YET RECRUITING·Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)
Conditions: Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma·Matched via name phrase
- NCT07014540·NOT YET RECRUITING·A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
Conditions: Neuroendocrine Carcinomas (NEC)·Matched via name phrase
- NCT07738159·NOT YET RECRUITING·Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma
Conditions: Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) · QL1706 · Lenvatinib · Chemotherapy·Matched via name phrase
- NCT07038096·RECRUITING·ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Conditions: Small Cell Lung Cancer · Neuroendocrine Carcinoma·Matched via name phrase
- NCT05882058·RECRUITING·DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Conditions: Small Cell Lung Carcinoma · Neuroendocrine Neoplasms · Extra-pulmonary Neuroendocrine Carcinoma·Matched via name phrase
- NCT07707895·NOT YET RECRUITING·DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Conditions: Small Cell Lung Cancer · Large Cell Neuroendocrine Lung Carcinoma · Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology · Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology·Matched via name phrase
- NCT05747729·RECRUITING·A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Conditions: Neuroendocrine Carcinoma·Matched via name phrase
- NCT06814496·RECRUITING·Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Conditions: Melanoma · Medullary Thyroid Cancer · Sinonasal Undifferentiated Carcinoma · Esthesioneuroblastoma·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06541652·RECRUITING·A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Conditions: Hepatocholangiocarcinoma · Fibrolamellar Carcinoma · Hepatic Epithelioid Hemangioendothelioma · Hepatoblastoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (4)
- isrctn·ISRCTN12812346·Recruiting·Study of etoposide carboplatin chemotherapy in combination with pembrolizumab and lenvatinib therapy in advanced high-grade neuroendocrine tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10996604·No longer recruiting·Second-line therapy for patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16419921·No longer recruiting·The survival and quality of life benefits of melatonin when administered to cancer patients at the optimal time of day
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16279802·No longer recruiting·ABLE Trial – Afatinib Before Lung surgEry: a study investigating the effect of giving a course of a targeted tablet treatment called afatinib to patients with potentially curable non-small cell lung cancer during the short interval between their diagnosis and the removal of their cancer by surgery
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Primary hepatic neuroendocrine carcinoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary hepatic neuroendocrine carcinoma" OR "PHNEC" OR "hepatic neuroendocrine carcinoma" OR "liver neuroendocrine cancer" OR "liver neuroendocrine carcinoma" OR "neuroendocrine carcinoma of liver" OR "neuroendocrine carcinoma of the liver" OR "primary liver neuroendocrine carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary hepatic neuroendocrine carcinoma" OR "PHNEC" OR "hepatic neuroendocrine carcinoma" OR "liver neuroendocrine cancer" OR "liver neuroendocrine carcinoma" OR "neuroendocrine carcinoma of liver" OR "neuroendocrine carcinoma of the liver" OR "primary liver neuroendocrine carcinoma"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"neuroendocrine carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HNEC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T07:06:06.585Z
